No Data
Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy?
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Express News | Jazz Pharmaceuticals PLC - Revolving Credit Facility Maturity Date Extended to November 26, 2029
Express News | Jazz Pharmaceuticals PLC - Amends Credit Agreement to Increase Commitments
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
No Data
No Data
